Hybio Pharmaceutical Forecasts 502%-531% Jump in Q1-Q3 Net Profit

The striking part is the divergence inside the forecast: revenue growth of roughly 80% is translating into a far larger profit jump, which points to operating leverage or a favourable mix shift rather than pure volume. The simultaneous sharp rise in R&D on the HY3003 trispecific and small nucleic acid programmes suggests the company is funding pipeline work out of current earnings rather than sacrificing near-term profitability. Whether that R&D intensity continues, and whether the unaudited figures hold through formal reporting, is the open question.